Investor Presentation Q1 2018
Investor Presentation
First three months of 2018
Slide 30
Novo Nordisk R&D strategy and priorities
STRATEGIC PRIORITIES
Strengthen leadership in
DIABETES CARE
Strengthen leadership in
OBESITY CARE
Pursue leadership in
HAEMOPHILIA
Strengthen leadership in
GROWTH DISORDERS
Expand into other
SERIOUS CHRONIC DISEASES
R&D PRIORITIES
Develop disruptive insulin and GLP-1 based products with
distinct clinical and/or delivery advantages
Develop novel mechanisms that reverse the course of
diabetes, act as insulin sensitisers and improve hard
clinical endpoints
Develop new biologics combined with GLP-1 to achieve
>15% weight loss
Pursue subcutaneous delivery of long-acting coagulation
factors and bypassing agents
Bring once-weekly growth hormone to market and expand
indications
Enter NASH, CVD and CKD by leveraging GLP-1 and other
internal assets as well as licensing external opportunities
Innovate to
improve
patient
outcomes and
drive growth
CKD: Chronic kidney disease; CVD: Cardiovascular disease; NASH: Non-alcoholic steatohepatitis
changing
diabetes
novo nordiskView entire presentation